4mmm

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
m (Protected "4mmm" [edit=sysop:move=sysop])
Line 1: Line 1:
-
'''Unreleased structure'''
+
==Human Pdrx5 complex with a ligand BP7==
 +
<StructureSection load='4mmm' size='340' side='right' caption='[[4mmm]], [[Resolution|resolution]] 1.47&Aring;' scene=''>
 +
== Structural highlights ==
 +
<table><tr><td colspan='2'>[[4mmm]] is a 4 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4MMM OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4MMM FirstGlance]. <br>
 +
</td></tr><tr><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BP7:1,1-BIPHENYL-3,4-DIOL'>BP7</scene><br>
 +
<tr><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4k7i|4k7i]], [[4k7n|4k7n]], [[4k7o|4k7o]]</td></tr>
 +
<tr><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Peroxiredoxin Peroxiredoxin], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=1.11.1.15 1.11.1.15] </span></td></tr>
 +
<tr><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4mmm FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4mmm OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4mmm RCSB], [http://www.ebi.ac.uk/pdbsum/4mmm PDBsum]</span></td></tr>
 +
<table>
 +
<div style="background-color:#fffaf0;">
 +
== Publication Abstract from PubMed ==
 +
Fragment-based drug design is one of the most promising approaches for discovering novel and potent inhibitors against therapeutic targets. The first step of the process consists of identifying fragments that bind the protein target. The determination of the fragment binding mode plays a major role in the selection of the fragment hits that will be processed into drug-like compounds. Comparing the binding modes of analogous fragments is a critical task, not only to identify specific interactions between the protein target and the fragment, but also to verify whether the binding mode is conserved or differs according to the fragment modification. While X-ray crystallography is the technique of choice, NMR methods are helpful when this fails. We show here how the ligand-observed saturation transfer difference (STD) experiment and the protein-observed 15N-HSQC experiment, two popular NMR screening experiments, can be used to compare the binding modes of analogous fragments. We discuss the application and limitations of these approaches based on STD-epitope mapping, chemical shift perturbation (CSP) calculation and comparative CSP sign analysis, using the human peroxiredoxin 5 as a protein model.
-
The entry 4mmm is ON HOLD until Paper Publication
+
Comparing Binding Modes of Analogous Fragments Using NMR in Fragment-Based Drug Design: Application to PRDX5.,Aguirre C, Brink TT, Guichou JF, Cala O, Krimm I PLoS One. 2014 Jul 15;9(7):e102300. doi: 10.1371/journal.pone.0102300., eCollection 2014. PMID:25025339<ref>PMID:25025339</ref>
-
Authors: Guichou, J.F.
+
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
-
 
+
</div>
-
Description: Human Pdrx5 complex with a ligand BP7
+
== References ==
 +
<references/>
 +
__TOC__
 +
</StructureSection>
 +
[[Category: Peroxiredoxin]]
 +
[[Category: Guichou, J F.]]
 +
[[Category: Enzyme]]
 +
[[Category: Oxidoreductase]]

Revision as of 07:39, 30 July 2014

Human Pdrx5 complex with a ligand BP7

4mmm, resolution 1.47Å

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Views
Personal tools
Navigation
Toolbox